Research-use, laboratory certification and test authorization
In one sentence
Research-use labeling, laboratory certification and product authorization answer different questions about a test and do not form one universal ladder of clinical usefulness.
The intuition
A driver's license, a vehicle inspection and a route map tell you different things. None can stand in for all the others. Testing labels work similarly: one describes intended use, another describes the laboratory, and another describes a product's regulatory status.
The comparison is only a memory aid. The precise rules depend on the test, jurisdiction and intended use. Start by asking what the label actually belongs to.
How it works
Research use only (RUO) is an intended-use label on a research product. It does not establish that the product is suitable for clinical diagnosis. A research result may motivate a question, but the label does not make it a validated treatment-selection report.
A laboratory-developed test (LDT) describes a test developed and used within a laboratory. That term describes where and how the test is made, rather than how useful it is. It is not a synonym for research-only testing, and it is not a statement that the Food and Drug Administration (FDA) has approved the test.
The Clinical Laboratory Improvement Amendments (CLIA) program sets standards for laboratories testing human specimens for health assessment or diagnosis, prevention or treatment. Laboratory certification concerns laboratory quality and applicable requirements. It does not establish clinical validity or utility for every claimed use of every test offered there.
FDA authorization concerns a specific product and intended use through an applicable regulatory pathway. Clearance, approval and emergency authorization have different meanings. When someone says “FDA-approved,” request the actual product record and labeling. Check the specimen, disease, biomarker, purpose and limitations.
A companion diagnostic provides information essential to the safe and effective use of a corresponding treatment. A biomarker assay does not become a companion diagnostic merely because its report lists drugs.
| Label or status | What to check | What it does not establish alone |
|---|---|---|
| RUO | Which product or component carries the label? | Clinical diagnostic suitability |
| LDT | Which laboratory developed and performs the test? | FDA approval or demonstrated patient benefit |
| CLIA | Which laboratory and certification scope? | Every clinical claim about its reports |
| FDA-cleared or approved test | Exact product, pathway and intended use | Uses outside the labeling |
| Companion diagnostic | Corresponding treatment and label-defined context | Benefit from any drug sharing a target name |
Why it matters in cancer
The same company may offer separate research and clinical services. A clinical report and a research file can look equally polished. Ask which service produced this result and what decision it is validated to support.
For the evidence questions behind those labels, use analytical validity, clinical validity and clinical utility.
Worked example
A fictional laboratory has CLIA certification and offers a new research score. Its brochure says the score predicts benefit from Drug A. Certification identifies a laboratory-quality framework. It does not supply the missing study of that particular score, population and treatment.
Common confusions
- Laboratory certification belongs to the laboratory; product authorization belongs to the product and intended use.
- LDT and RUO are not interchangeable.
- A regulatory label is not a universal evidence grade.
- “FDA registered” is not the same claim as an approved or cleared test.
Related concepts
Sources and scope
U.S. regulatory source check: October 9, 2026. Expert and learner review remain pending. Rules can change, so verify a specific test's current status before using it.
Current LDT correction: FDA states that the 2024 LDT final rule was vacated on March 31, 2025. FDA reverted the regulatory text on September 19, 2025. The vacated rule's phaseout schedule should not be taught as current policy. This procedural update does not establish the validity of a particular test.
- FDA: laboratory-developed tests — current vacatur and regulatory-text update.
- CMS: Clinical Laboratory Improvement Amendments — laboratory-quality program.
- CMS: LDT and CLIA questions — analytical oversight differs from clinical validity; explanatory document predates the vacated rule.
- FDA: research-use-only diagnostic-product guidance — intended-use labeling.
- FDA: companion diagnostics — treatment-linked use.